Neuren Pharmaceuticals

As of June 30, Neuren reported AUD 287 million in cash and USD 23.1 million in license revenue for the half-year, and confirmed an annual license revenue guidance of USD 53–56 million. The company is launching a dividend program with a fully franked interim dividend of AUD 0.15 per share and expects an available dividend pool of AUD 48–51.6 million. Commercially, DAYBUE supports cash generation, while the phase‑III KOALA study of NNZ‑2591 is progressing (15 sites activated, recruitment ongoing). Management emphasises financial coverage without a capital raise and keeps the cost estimate for the NNZ‑2591 program at USD 80–90 million. » Más en de.investing.com

Neuren Pharma's stock rose over 11% following the grant of a patent for its drug NNZ-2591 to treat Pitt Hopkins Syndrome, a rare neurodevelopmental disorder. Clinical trials showed neuropsychological improvements in patients, and there are currently no approved treatments for the condition. Despite recent volatility and a 33% drop in one-year returns, the patent news marks a positive development for the company. » Más en themarketonline.com.au